The South Korea Fabry disease market size stood at around USD xx million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx % during the forecast period.
Fabry disease is caused by a mutation in the galactosidase alpha gene, which leads to absent or deficient function of the lysosomal enzyme α-galactosidase A. It is a progressive lysosomal storage disease. As GL-3 is not decomposed and accumulates, various clinical symptoms appear throughout the body, including eyes, heart, kidneys, and skin. As Fabry disease is a progressive disease that worsens with age, experts say early diagnosis and treatment are of the utmost importance. Main symptoms and co-morbidities for Fabry disease include angiokeratoma, cornea verticillate (corneal whirling), hearing loss, tinnitus, proteinuria, cardiac hypertrophy & arrhythmias, sweating dysfunction.
Increasing government efforts towards the improvement of the healthcare sectors as well as the introduction of new therapies, and many drugs that are in pipelines will drive the market growth in the near future. Additionally, the increasing awareness about the enzyme replacement therapy among people and rising healthcare expenditure towards research and development of new drugs and the acceptance of technologically superior medical devices is expected to drive the market growth.
It is confirmed that there were about 200 Fabry disease patients in Korea as of 2018 but considering the frequency of occurrence of about 1 in 40,000 to 60,000 people, there are likely to be many undiagnosed patients. These undiagnosed cases will impede the market growth.